Found 8 matching trials
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
PHASE1The purpose of this study is to determine the recommended Phase 2 dose(s) (...
Status
Active Not Recruiting
Location
Mayo Clinic Arizona
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
PHASE1The purpose of this study is to identify the recommended phase 2 combinatio...
Location
Florida Cancer Specialists
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
PHASE3The purpose of this study is to find out whether treatment with pasritamig ...
Location
Arizona Clinical Trials
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
PHASE1The purpose of this study is to identify the recommended phase 2 regimen(s)...
Location
Florida Cancer Specialists
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
PHASE1The purpose of this study is to determine the recommended phase 2 dose(s) (...
Status
Active Not Recruiting
Location
Columbia University Medical Center Herbert Irving Pavilion
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
PHASE1The purpose of this study is to identify the recommended phase 2 combinatio...
Location
Florida Cancer Specialists
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
PHASE1The purpose of Parts 1, 2A, and 2B of the study is to determine the recomme...
Location
University of Colorado Anschutz Medical Campus
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
PHASE3The purpose of this study is to evaluate the overall survival (length of ti...
Location
University of California at San Diego